8-K: Syndax Reports Strong 2025 Revenue, Nears Profitability

Syndax Pharmaceuticals announced preliminary strong 2025 revenue for Revuforj and Niktimvo, ending the year with $394 million in cash and projecting profitability.

Summary

• Preliminary (unaudited) U.S. net product revenue for Revuforj (revumenib) was approximately $44 million for the fourth quarter of 2025 and $125 million for the full year 2025.
• Revuforj net revenue increased by approximately 38% in the fourth quarter of 2025 compared to the third quarter of 2025, with total prescriptions increasing by 35% following FDA approval in R/R NPM1m AML on October 24, 2025.
• Preliminary (unaudited) U.S. net product revenue for Niktimvo (axatilimab-csfr) was $56 million for the fourth quarter of 2025 and $152 million for the full year 2025.
• Syndax expects its share of Niktimvo net commercial profit to amount to approximately 25-30% of net revenue.
• The company ended 2025 with approximately $394 million in preliminary (unaudited) cash, cash equivalents, and marketable securities.
• Syndax is fully funded through profitability, anticipating its cash position combined with product revenue and interest income will enable this.
• Revuforj received the 'Best New Drug' award at the Scrip Awards 2025.
• Initiated REVEAL-ND, a Phase 3 trial for revumenib in newly diagnosed NPM1m AML, in November 2025.
• Initiated a multi-regional Managed Access Program to expand access to Revuforj outside the U.S.

Sentiment

Score: 8

Explanation: The filing reports strong preliminary revenue growth for both commercial products, a healthy cash position, and a clear path to profitability, indicating significant positive momentum and successful execution of commercial and clinical strategies. The only minor negative is the preliminary nature of the financial data.

Positives

• Strong preliminary U.S. net product revenue for Revuforj: $44 million in Q4 2025 and $125 million for full year 2025.
• Significant acceleration in Revuforj demand, with a 38% increase in Q4 2025 revenue over Q3 2025 and a 35% increase in prescriptions.
• Robust preliminary U.S. net product revenue for Niktimvo: $56 million in Q4 2025 and $152 million for full year 2025.
• Healthy cash position of approximately $394 million in cash, cash equivalents, and marketable securities as of December 31, 2025.
• The company is fully funded through profitability, indicating strong financial stability and a positive future outlook.
• Revuforj received the 'Best New Drug' award at the Scrip Awards 2025, recognizing its therapeutic advance.
• Advancement of the pipeline with the initiation of the Phase 3 REVEAL-ND trial for revumenib and a multi-regional Managed Access Program for Revuforj.
• Secured a third FDA approval in 2025 and successfully executed the launches of Revuforj and Niktimvo.

Negatives

• The financial results are preliminary and unaudited, subject to adjustment, and do not present all information necessary for a complete understanding of the company's financial condition or results of operations.

Risks

• Preliminary financial results are unaudited and subject to adjustment, and the ongoing audit could result in changes to the reported information.
• Forward-looking statements involve risks and uncertainties, and actual results may differ materially from expectations.
• Potential factors causing differences include unexpected safety or efficacy data observed during preclinical or clinical trials, lower than expected clinical trial site activation or enrollment rates, changes to Revuforj's or Niktimvo's commercial availability, changes in expected or existing competition, changes in the regulatory environment, failure of collaborators to support or advance collaborations or product candidates, and unexpected litigation or other disputes.

Future Outlook

Syndax expects to drive Revuforj and Niktimvo net revenue growth and invest thoughtfully in pipeline development and data generation to fuel further growth. The company anticipates that its cash position, combined with anticipated product revenue and interest income, will enable it to reach profitability. Key milestones for 2026 include completing enrollment in the MAXPIRe Phase 2 trial, advancing global enrollment in EVOLVE-2 and REVEAL-ND Phase 3 trials, initiating the RAVEN Phase 2 trial, and initiating a program for revumenib in myelofibrosis.

Management Comments

• "2025 was a transformational year for Syndax as we secured our third FDA approval and successfully executed the launches of Revuforj and Niktimvo, proving our ability to deliver innovative therapies for patients and advancing the company towards profitability."
• "With strong momentum and further acceleration of growth going into 2026, we look forward to continuing to build Revuforj and Niktimvo into industry leading franchises and advancing our lifecycle and frontline programs designed to expand our patient impact and unlock the multi-billion-dollar potential of both medicines."

Industry Context

The biopharmaceutical industry, particularly in oncology and rare diseases, is highly competitive and driven by innovation and successful clinical development. Syndax's focus on menin inhibition (Revuforj for AML) and CSF-1R blocking (Niktimvo for chronic GVHD) positions it in areas with significant unmet medical needs. The successful launches and revenue growth of these two FDA-approved therapies demonstrate effective commercialization in a competitive landscape, while pipeline advancements aim to expand market reach and address broader patient populations, aligning with industry trends of lifecycle management and combination therapies.

Comparison to Industry Standards

• The rapid revenue growth for Revuforj (38% Q-o-Q) and Niktimvo indicates strong market acceptance post-launch, which is a positive sign for newly approved therapies in the biopharmaceutical sector. These figures suggest a robust initial commercialization phase, comparable to successful oncology drug launches that aim for rapid uptake.
• The company's statement of being 'fully funded through profitability' is a significant positive differentiator, as many early-to-mid-stage biopharmaceutical companies frequently require additional capital raises, which can dilute existing shareholders. This suggests strong financial management and commercial execution compared to peers still in heavy R&D phases.
• The initiation of multiple Phase 3 and Phase 2 trials (REVEAL-ND, EVOLVE-2, RAVEN, MAXPIRe) demonstrates a commitment to expanding indications and market potential, a common strategy among successful biopharma companies to maximize asset value.
• The 'Best New Drug' award for Revuforj at the Scrip Awards 2025 highlights external recognition of its therapeutic value, placing it among leading innovative therapies in the industry.

Stakeholder Impact

• Shareholders: Positive impact due to strong revenue growth, healthy cash position, and projected profitability, potentially leading to increased share value.
• Patients: Positive impact through expanded access to Revuforj via a Managed Access Program and ongoing clinical trials aiming to broaden indications and treatment options for AML, chronic GVHD, and IPF.
• Employees: Positive impact from a growing, successful company with expanding pipeline and commercial operations.
• Partners (Incyte, UCB): Positive impact from successful commercialization of Niktimvo and continued development of axatilimab.

Next Steps

• Report full year 2025 results in early 2026.
• Complete enrollment in MAXPIRe Phase 2 trial of axatilimab in IPF in January 2026.
• Present topline data from MAXPIRe Phase 2 trial in the second half of 2026.
• Advance global enrollment in EVOLVE-2 (unfit NPM1m and KMT2Ar AML) and REVEAL-ND (fit NPM1m) Phase 3 frontline trials of revumenib.
• Initiate RAVEN, a Phase 2 collaborative trial of revumenib in newly diagnosed KMT2Ar patients, in 2026.
• Further leadership in menin and CSF-1R inhibition through publication and presentation of clinical trial data and real-world evidence.
• Initiate a program in 2026 to generate proof-of-principle clinical data with revumenib in myelofibrosis (MF).

Key Dates

Recommendation

The filing demonstrates exceptional commercial execution with two recently approved drugs, Revuforj and Niktimvo, showing significant revenue growth and accelerating demand. The company's strong cash position of $394 million and explicit statement of being 'fully funded through profitability' de-risks future operations and removes the overhang of potential dilution. The robust pipeline advancement, including multiple Phase 3 trials and new program initiations, indicates sustained long-term growth potential. The 'Best New Drug' award for Revuforj further validates its therapeutic value. These factors collectively present a compelling investment case for strong upside potential.

Keywords

Syndax Pharmaceuticals, SNDX, Revuforj, revumenib, Niktimvo, axatilimab-csfr, menin inhibitor, CSF-1R, AML, NPM1m, KMT2Ar, chronic GVHD, oncology, biopharmaceutical, FDA approval, financial results, revenue, cash position, clinical trials, J.P. Morgan Healthcare Conference